Savulescu Warns that “Love-Diminishing” Drugs could be Used for Gay “Conversion Therapy”
By Xavier Symons,
BioEdge
| 10. 12. 2013
In recent years Oxford bioethicist Julian Savulescu has written extensively about the neuro-enhancement of human relationships. In a number of papers, he has studied the ethics of using drugs to strengthen or improve romantic relationships. But how about the use of “individual, voluntary use of love-diminishing biotechnology”? In other words, drugs which would inhibit or reduce love or sexual attraction. If love is essentially chemical, the tap can be turned on or off.
Although this is currently not feasible, Savulescu and co-authors Brian D. Earp and Anders Sandberg warn that drugs could be used to reverse homosexual inclinations. In a controversial paper in the
American Journal of Bioethics: Neuroscience, “
Brave new love: The threat of high-tech ‘conversion’ therapy and the bio-oppression of sexual minorities”, they examine the ethics of using drugs to “normalize” people with atypical sexual desires.
They conclude that the use of conversion drugs on minors should be illegal but “in rare cases” they could be used by consenting adults, even if they are religious fundamentalists. “It seems hard to maintain… that John Stuart Mill’s...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...